Johnson & Johnson (NYSE:JNJ) is RBO & Co. LLC's 4th Largest Position

RBO & Co. LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 0.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 213,574 shares of the company's stock after acquiring an additional 1,654 shares during the quarter. Johnson & Johnson makes up 5.0% of RBO & Co. LLC's portfolio, making the stock its 4th largest holding. RBO & Co. LLC's holdings in Johnson & Johnson were worth $30,887,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Principal Financial Group Inc. boosted its stake in shares of Johnson & Johnson by 10.5% in the third quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company's stock worth $562,723,000 after acquiring an additional 329,473 shares during the period. Invst LLC grew its holdings in Johnson & Johnson by 394.0% during the 3rd quarter. Invst LLC now owns 10,290 shares of the company's stock valued at $1,668,000 after buying an additional 8,207 shares in the last quarter. McIlrath & Eck LLC raised its position in shares of Johnson & Johnson by 10.7% during the third quarter. McIlrath & Eck LLC now owns 2,892 shares of the company's stock valued at $469,000 after buying an additional 279 shares during the last quarter. Passumpsic Savings Bank purchased a new position in shares of Johnson & Johnson during the third quarter valued at about $262,000. Finally, Te Ahumairangi Investment Management Ltd grew its holdings in Johnson & Johnson by 10.1% during the 3rd quarter. Te Ahumairangi Investment Management Ltd now owns 50,765 shares of the company's stock valued at $8,180,000 after buying an additional 4,640 shares in the last quarter. Institutional investors own 69.55% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on JNJ shares. Stifel Nicolaus cut their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating for the company in a report on Thursday, January 23rd. Bank of America cut their price objective on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a research report on Thursday, April 10th. Leerink Partners dropped their price target on shares of Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating for the company in a research note on Thursday, January 23rd. Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Finally, Morgan Stanley upped their price target on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 16th. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $171.82.

Insider Activity

In other news, EVP Timothy Schmid sold 403 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares of the company's stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the firm's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Down 1.2 %

Shares of JNJ stock traded down $1.89 during trading hours on Thursday, reaching $154.42. 7,317,524 shares of the company's stock were exchanged, compared to its average volume of 7,889,701. The stock has a market cap of $371.54 billion, a PE ratio of 23.22, a PEG ratio of 2.56 and a beta of 0.49. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The stock's fifty day moving average price is $159.05 and its two-hundred day moving average price is $154.73. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 3.37%. The ex-dividend date of this dividend is Tuesday, May 27th. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's payout ratio is presently 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.